Maurizio Fava, M.D.
|Title||Slater Family Professor of Psychiatry|
|Institution||Massachusetts General Hospital|
|Address||Massachusetts General Hospital|
55 Fruit St
Boston MA 02114
||ACNP Travel Award|
||Edwin Dunlop Memorial Scholarship|
||Honorable Mention, APA/Wisniewski Young Psychiatrist Research Award|
||Young Investigator Award|
||Nomination HMS 1995 Award for Excellence in Mentoring|
2000||Elected by Peers for Inclusion in Best Doctors in America|
||Honorable Mention, MGH Psychiatry Residency Class of 1996 Teaching Award|
||Third Place Winner, 1996 Dorfman Journal Paper Award|
||Hugo DeCuyper Lecture|
2000||Nomination, HMS 2000 A. Clifford Barger Award for Excellence in Mentoring|
||Robert Kellner Lecture/Robert Kellner Research Symposium|
||Partners in Excellence Award|
||Nomination, HMS School Excellence in Mentoring Award|
||Outstanding Psychiatrist Award|
||Psychopharmacology Supervision Award|
||Distinguished Fellow Award|
||Peer Review Circle of Honor|
||Nomination, HMS Excellence in Mentoring Award|
Narrative Report of Research, Teaching, and Clinical Contributions:
Dr. Fava is currently Vice Chair, Department of Psychiatry and Director of the Depression Clinical and Research Program (DCRP) at the Massachusetts General Hospital, as well as Professor of Psychiatry at Harvard Medical School. Director of the DCRP since 1990, Dr. Fava has expanded the program significantly, increasing the spending budget from $100,000 to over $3,000,000 per year. His research program’s impact on the field has also increased over the years, as reflected by over 50 presentations/year at National Meetings and over 30 original articles/year published in refereed journals. Under Dr. Fava’s direction, the DCRP has become one of the leading centers for the study of Unipolar Depressive Disorders in the country. Over the past 16 years, Dr. Fava has also been successful in obtaining more than $23,000,000 in funding for his program, as principal or co-principal investigator, from the National Institute of Health, other federal agencies, foundations, and pharmaceutical industries. Dr. Fava is also the co-Principal Investigator with Dr. A.John Rush of a $35,000,000 NIMH contract to study treatment-resistant depression, STAR*D, whose findings have been published in journals such NEJM and JAMA. In addition to his numerous clinical trials and studies in treatment resistant depression, Dr. Fava has contributed significantly to the field of psychiatric research in a number of other areas. He has identified a subtype of depressive disorder characterized by marked irritability and “anger attacks.” His innovative work has led to the discovery that these individuals present a blunted prolactin response to fenfluramine challenge, are more likely to have white matter hyperintensities, and may selectively respond to SSRIs. In addition, Dr. Fava has conducted important investigations on the role of folate deficiency in depression and on the efficacy in depression of one carbon cycle elements with putative antidepressant effects such as s-adenosyl-methionine (SAMe) and methylfolate. His pioneering work in this area has led to his current-R-01 grant on the efficacy of SAMe in major depressive disorder (MDD). He has conducted and published the first prospective, placebo-controlled study of discontinuation-emergent adverse events of the newer antidepressants and he has designed and developed a protocol for the first, large multicenter study on the effects of abrupt interruption of SSRI treatment. He has completed a large single-site study of bupropion augmentation of the nicotine patch in depressed smokers (as part of one of his previous R-01s) and he is currently the PI of a large U-01 aimed at developing new treatments for nicotine dependence. He has developed with Dr. David Schoenfeld a novel design to address the problem of excessive placebo response in antidepressant trials and to markedly reduce sample size requirements for trials (a patent has been filed on his behalf by Partners on this design). He has also been very interested in developing new instruments to measure the effects of antidepressants treatments, and several of his validated instruments (such as the DESS scale, SFQ scale, and the CPFQ scale) are being used by clinical investigators in the US and abroad. Because of his ability to collaborate very effectively with PCPs in research projects such as STAR*D, he has been recently named co-Medical Director of Partners Research and Education Program (PREP). With respect to his publications, Dr. Fava has authored or co-authored over 300 original articles published in refereed medical journals with international circulation. The citation impact of Dr. Fava’s work is extremely high, as his articles have been cited more than 3,000 times in the literature. He has also edited four books, and he has published more than 50 chapters and 450 abstracts.
Dr. Fava has an excellent track record as a teacher and has been very active in instructing and supervising psychiatric residents and fellows. Over the past 16 years, Dr. Fava has also trained and mentored a number of research fellows in his program, many of whom have continued to work in the area of psychiatric research following completion of their fellowship. Dr. Fava has also been the mentor/sponsor for several successful NARSAD, APA, and K Award fellowship applications (he is currently mentoring six K-23 Award recipients), and he has been nominated several times for the Harvard Medical School Award for Excellence in Mentoring. Over the past several years, he has organized and chaired numerous symposia and has served on many advisory panels for pharmaceutical companies. In addition, he has reviewed grant proposals and specific RFP concepts/contracts for the National Institute of Mental Health, the National Institute of Drug Abuse, and currently serves on an NCCAM study section. Dr. Fava is currently the co-director of the Psychopharmacology Course of the Harvard Medical School Department of Continuing Education, one of the most highly attended courses in the country, with approximately 800 participants each year. Dr. Fava has also lectured extensively, with over 250 presentations at national and international meetings and conferences.
He is considered an expert psychopharmacologist in the area of depression and frequently provides consultations to difficult cases referred to him from all over the world. He has been for the past nine years in charge of a large PO group practice of clinicians specialized in the treatment of patients with mood disorders, and his leadership skills have been key to the financial success of this group.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Click the "See All" links for more information and interactive visualizations!
People who are also in this person's primary department.